NCT07555301Not yet recruiting
Clinical Experience With Sparsentan in Switzerland in IgA Nephropathy
Source: ClinicalTrials.gov · Last updated 29 Apr 2026
Brief summary (registry, in English)
An observational study tracking the clinical course of patients with IgA nephropathy.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 50 (estimated)
- First submitted
- 21 Apr 2026
- Start date
- 1 Jun 2026
- Primary completion date
- 31 Dec 2028
- Lead sponsor
- Waid City Hospital, Zurich
- Diseases
- IgA nephropathy
- NCT number
- NCT07555301
What you commit to
- Study type: Observational
- Planned participants: 50
- From 1 Jun 2026 to the primary completion date, 31 Dec 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Age
- age \< 18y
Who the study is looking for
- IgA Nephropathy, Use of Sparsentan
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Stadtspital Zürich Coordinator of this site? Confirm its status | Zurich | Switzerland | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.